scispace - formally typeset
Search or ask a question
Institution

Eli Lilly and Company

CompanyIndianapolis, Indiana, United States
About: Eli Lilly and Company is a company organization based out in Indianapolis, Indiana, United States. It is known for research contribution in the topics: Population & Receptor. The organization has 17826 authors who have published 22835 publications receiving 946714 citations. The organization is also known as: Eli Lily.
Topics: Population, Receptor, Placebo, Insulin, Agonist


Papers
More filters
Journal ArticleDOI
21 Feb 2019
TL;DR: In this article, a review of existing early clinical manifestations of Alzheimer's disease and a path to the respective sensor and mobile/wearable device usage to acquire domain-centric data towards objective, high frequency and passive digital phenotyping is presented.
Abstract: Alzheimer’s Disease (AD) represents a major and rapidly growing burden to the healthcare ecosystem. A growing body of evidence indicates that cognitive, behavioral, sensory, and motor changes may precede clinical manifestations of AD by several years. Existing tests designed to diagnose neurodegenerative diseases, while well-validated, are often less effective in detecting deviations from normal cognitive decline trajectory in the earliest stages of the disease. In the quest for gold standards for AD assessment, there is a growing interest in the identification of readily accessible digital biomarkers, which harness advances in consumer grade mobile and wearable technologies. Topics examined include a review of existing early clinical manifestations of AD and a path to the respective sensor and mobile/wearable device usage to acquire domain-centric data towards objective, high frequency and passive digital phenotyping.

204 citations

Patent
18 Apr 1996
TL;DR: In this paper, a multi-cartridge dispenser for delivering two liquid medications through a single needle is described, which includes independent dual channel metering mechanism, dual channel drive mechanisms, and dual channel lock and pullback mechanisms.
Abstract: A multi-cartridge dispenser for delivering two liquid medications through a single needle. The dispenser includes independent dual channel metering mechanism, dual channel drive mechanisms, and dual channel lock and pullback mechanisms. The wing must be in its "up" position for metering to take place. The wing reciprocatingly moves a driver between a pre-injection position and a post-injection position to reciprocatingly advance the leadscrews upon an injection stroke. The dosage indicator automatically rotates to its initial zero position upon the injection stroke. The lock and pullback mechanism automatically prevents rotation of the leadscrew upon metering and injection. It also locks out the cartridge retainers so that the retainers can be removed from the housing only while the wing is in its "down" position. The pullback sleeve unloads a pullback key during a cartridge change in order to enable the leadscrew to be spun freely back to its home position.

204 citations

Journal ArticleDOI
01 Sep 2003-Bone
TL;DR: The pharmacokinetic profiles suggest that the anabolic or catabolic response of bone to PTH(1-34) is determined primarily by the length of time each day that serum concentrations of P TH remain above baseline levels of endogenous PTH and only secondarily by the Cmax or AUC achieved.

204 citations

Journal ArticleDOI
TL;DR: The findings support a rescreening interval of 5 years or longer after a normal colonoscopic examination among persons with no colorectal neoplasia on initial screening colonoscopy, which is extremely low and the 5-year risk of coloreCTal cancer isextremely low.
Abstract: Background The appropriate interval for endoscopic rescreening after a negative colonoscopic examination is uncertain. Methods We identified persons with no adenomas on baseline screening colonoscopy who returned at 5 years for follow-up colonoscopy. Findings were categorized according to the most advanced lesion present: no polyp, a hyperplastic polyp, a tubular adenoma less than 1 cm in diameter, an advanced adenoma (a tubular adenoma ≥1 cm in diameter or a polyp with villous histologic features or high-grade dysplasia), or a cancer.

204 citations

Journal ArticleDOI
TL;DR: It is suggested that a lower response to reward anticipation in the ventral striatum may be a vulnerability factor for the development of early nicotine use.
Abstract: Objective:Adolescents are particularly vulnerable to addiction, and in the case of smoking, this often leads to long-lasting nicotine dependence. The authors investigated a possible neural mechanism underlying this vulnerability. Method:Functional MRI was performed during reward anticipation in 43 adolescent smokers and 43 subjects matched on age, gender, and IQ. The authors also assessed group differences in novelty seeking, impulsivity, and reward delay discounting. Results:In relation to the comparison subjects, the adolescent smokers showed greater reward delay discounting and higher scores for novelty seeking. Neural responses in the ventral striatum during reward anticipation were significantly lower in the smokers than in the comparison subjects, and in the smokers this response was correlated with smoking frequency. Notably, the lower response to reward anticipation in the ventral striatum was also observed in smokers (N=14) who had smoked on fewer than 10 occasions. Conclusions:The present findin...

203 citations


Authors

Showing all 17866 results

NameH-indexPapersCitations
Mark J. Daly204763304452
Irving L. Weissman2011141172504
Eric J. Topol1931373151025
Tony Hunter175593124726
Xiang Zhang1541733117576
Jerrold M. Olefsky14359577356
Stephen F. Badylak13353057083
George A. Bray131896100975
Lloyd Paul Aiello13150685550
Levi A. Garraway12936699989
Mark Sullivan12680263916
James A. Russell124102487929
Tony L. Yaksh12380660898
Elisabetta Dejana12243048254
Hagop S. Akiskal11856550869
Network Information
Related Institutions (5)
Pfizer
37.4K papers, 1.6M citations

98% related

Merck & Co.
48K papers, 1.9M citations

97% related

Novartis
50.5K papers, 1.9M citations

97% related

Hoffmann-La Roche
43K papers, 1.6M citations

93% related

National Institutes of Health
297.8K papers, 21.3M citations

91% related

Performance
Metrics
No. of papers from the Institution in previous years
YearPapers
20236
202287
2021815
2020868
2019732
2018742